Neoadjuvant and adjuvant therapy of intrahepatic cholangiocarcinoma

VernacularTitle:肝内胆管癌的新辅助与辅助治疗
Author: Yuxuan LIN ¹ ; Yong XIA ; Feng SHEN
Author Information

1. 海军军医大学第三附属医院肝外四科，上海　200438
Keywords: Bile duct neoplasms; Neoadjuvant therapy; Adjuvant therapy
From: Chinese Journal of Hepatobiliary Surgery 2023;29(7):552-556
CountryChina
Language:Chinese
Abstract: Intrahepatic cholangiocarcinoma (ICC) refers to adenocarcinoma originating from the secondary bile ducts and their branches within the liver, with high malignancy and poor prognosis. Radical surgical resection is currently the only possible way to cure ICC, but only some patients meet the surgical standards, and even with surgical resection, about 60% of patients will relapse within 1~2 years. Neoadjuvant therapy and adjuvant therapy are important perioperative treatment methods for ICC, with the aim of reducing postoperative recurrence and improving postoperative survival. This article aims to elaborate on the current status and research progress of neoadjuvant therapy and adjuvant therapy for ICC.